Watch theater presentation
Dr. Eran Eden
Dr. Eran Eden is the Co-founder and CEO of MeMed since its inception in 2009. He lead MeMed from an idea to a rapidly growing company that is pioneering the field of host-response technologies.
Dr. Debra Goff
Dr. Goff is an Infectious Diseases Specialist pharmacist at The Ohio State University Wexner Medical Center and global antibiotic stewardship expert.
Is it a bacterial or viral infection? Using host-response technologies to decode the immune system and aid antibiotic stewardship
What would your practice look like if you had a 15-minute test that could differentiate between a bacterial and viral infection? MeMed BV® is the first rapid and accurate (blinded and external validation) host-response technology for distinguishing between bacterial and viral infections in under 15 minutes, and it is changing the paradigm in infectious disease patient management.
At MeMed, a leader in host response technologies, we decode the body's complex signals into simple insights that improve people's lives. By leveraging our expertise in host-response profiling and machine-learning algorithms, we are creating a portfolio of tests that address tough clinical dilemmas.
Importantly, with the support of public and private partnerships, we have developed a point-of-need, rapid measurement platform called MeMed Key® to ensure timely availability of these novel tests during the clinician’s decision-making workflow.
Come join MeMed's Presentation Theater at IDWeek
Sheldon L. Kaplan, MD
Head, Pediatric Infectious Disease Section, Baylor College of Medicine
New Developments in Infectious Diseases Diagnostics:
112 - A Rapid Host-Protein Signature Based on TNF-related Apoptosis-Induced Ligand (TRAIL), Interferon Gamma Induced Protein-10 (IP-10) and C-Reactive Protein (CRP) Accurately Differentiates Between Bacterial and Viral Infection in Febrile Children: Apollo Sub-Study.
International Investigator Award Product Associate, MeMed
COVID-19 Complications, Co-infections and Clinical Outcomes:
32 - Host Immune-Protein Signature Combining TRAIL, IP-10 and CRP for Early and Accurate Prediction of Severe COVID-19 Outcome